BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics reported a Q1 2026 net loss of $2.1 million, with cash reserves dwindling to approximately $0.2 million as of March 31. The company highlighted its preparation for the Phase 3b ENDURANCE trial of NurOwn for ALS, noting that site activation and regulatory engagement are progressing but remain contingent on securing necessary financing.
Key figures
- Net Loss
- 2127000
- Revenue
- 0
- Offering Price
- 0.95
- Shares Offered
- 210526
- Ga Expense
- 1284000
- Rd Expense
- 762000
- Warrants Issued
- 252630
- Warrant Exercise Price
- 1.45
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.